文献速递免疫规划传染病防控与疫情报告

模块化Tag/Catcher病毒样颗粒展示SARS-CoV-2 RBD增强DNA疫苗小鼠免疫原性

Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice.
PubMed 文献 · Vaccine · 2026-09-05

本研究采用模块化Tag/Catcher衣壳病毒样颗粒(cVLP)技术,通过共给药两种质粒(分别编码RBD抗原和cVLP支架,各融合互补的Tag/Catcher结合伴侣),在小鼠体内诱导展示多拷贝RBD的cVLP组装。与编码可溶性RBD的对照DNA疫苗相比,该策略增强了中和抗体滴度和RBD特异性CD8+ T细胞应答。

要点

  • 模块化Tag/Catcher cVLP展示策略可提升DNA疫苗的中和抗体滴度
  • 该策略同时增强RBD特异性CD8+ T细胞应答
  • DNA疫苗低免疫原性问题或可通过cVLP展示技术改善

核心结论

  • 模块化Tag/Catcher cVLP展示可增强SARS-CoV-2 RBD DNA疫苗在小鼠中的免疫原性。

研究设计与样本

  • 小鼠实验研究,比较模块化cVLP展示RBD的DNA疫苗与编码可溶性RBD的对照DNA疫苗。

主要发现

  • 与对照DNA疫苗相比,模块化cVLP展示策略增强了中和抗体滴度。
  • 与对照DNA疫苗相比,模块化cVLP展示策略增强了RBD特异性CD8+ T细胞应答。

临床怎么用

  • 该策略可与DNA递送技术进展结合,用于提升DNA疫苗免疫原性。
  • Tag/Catcher cVLP技术或有助于DNA平台用于大流行准备和成本效益免疫。

局限性

  • 研究仅在小鼠中进行,尚未在人体验证。
  • DNA疫苗在人类中通常免疫原性较低,本策略的人体转化效果未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The COVID-19 pandemic highlighted the critical need for adaptable, rapid-response vaccine platforms. While mRNA vaccines enabled fast and scalable development, their stringent cold-chain requirements limited global accessibility. DNA vaccines offer a similarly fast and flexible vaccine design, but require far less complex manufacturing and distribution conditions, which is an advantage during a pandemic response. However, DNA vaccines have generally shown low immunogenicity in humans, which has hindered their clinical translation. Therefore, strategies that can enhance the potency of DNA vaccines are critical for realizing the full potential of this platform. Here, we apply a modular Tag/Catcher capsid virus-like particle (cVLP) technology to improve the immunogenicity of a DNA vaccine expressing the SARS-CoV-2 receptor-binding domain (RBD). Specifically, by administering a mixture of two plasmids, one encoding the RBD antigen and the other encoding a cVLP scaffold, each fused to a complementary Tag/Catcher binding partner, we induce in vivo assembly of cVLPs displaying multiple copies of the RBD antigen. In comparison to a control DNA vaccine encoding soluble RBD, the modular cVLP-display approach enhances both neutralizing antibody titers and RBD-specific CD8+ T-cell responses in mice. These findings demonstrate that the modular Tag/Catcher approach for cVLP display offers a widely applicable strategy for enhancing the immunogenicity of DNA vaccines, which could be combined with ongoing advances in DNA delivery for additive or synergistic benefit. Incorporating the Tag/Catcher cVLP technology may thus help establish the DNA platform as a viable tool for pandemic preparedness and cost-effective immunization in humans and animals.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Okholm AK, Fougeroux C, Hagen SH, et al. Virus-like particle display of the SARS-CoV-2 receptor-binding domain using a modular tag/catcher system enhances immunogenicity of a DNA vaccine in mice. Vaccine. 2026. PMID: 42700748. doi:10.1016/j.vaccine.2026.129117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。